A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg

Trial Profile

A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms PALADIN
  • Sponsors Alimera Sciences
  • Most Recent Events

    • 08 Nov 2017 According to an Alimera Sciences media release, updated data from this trial will be presented at 2017 Annual Meeting of the American Academy of Ophthalmology (AAO).
    • 09 Aug 2017 According to an Alimera Sciences media release, data will be presented at the 2017 American Society of Retinal Specialists (ASRS) Annual Meeting.
    • 01 May 2017 According to an Alimera Sciences media release, data from this trial will be presented during the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top